Overview

A Phase Ⅰb/Ⅱ Clinical Study of Crifortinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Status:
Not yet recruiting
Trial end date:
2024-10-18
Target enrollment:
Participant gender:
Summary
This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Crifortinib Besylate combined with chemotherapy in newly-treated adult subjects with AML
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.